Difference between revisions of "Translocations et al. in Hematological Cancers"
Jump to navigation
Jump to search
| [unchecked revision] | [unchecked revision] |
(Created page with "__TOC__ ==Chronic Myeloproliferative Diseases (MPD)== : +13 or trisomy 13 : +14 or trisomy 14 (solely) : +16 or trisomy 16 (solely) : +20 or trisomy 20 (solely...") |
|||
| Line 1: | Line 1: | ||
__TOC__ | __TOC__ | ||
| − | = | + | {| class="wikitable" |
| + | |+Translocations | ||
| + | |- | ||
| + | |'''Anomaly''' | ||
| + | |'''Associated Disorders''' | ||
| + | |- | ||
| + | |Bread | ||
| + | |Pie | ||
| + | |- | ||
| + | |Butter | ||
| + | |Ice cream | ||
| + | |- | ||
| + | |der(1)t(1;1)(p36;q21) | ||
| + | |[[NHL]],MDS | ||
| − | + | |} | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Myelodysplastic Syndromes (MDS)== | ==Myelodysplastic Syndromes (MDS)== | ||
Revision as of 09:56, 3 September 2015
| Anomaly | Associated Disorders |
| Bread | Pie |
| Butter | Ice cream |
| der(1)t(1;1)(p36;q21) | NHL,MDS |
Myelodysplastic Syndromes (MDS)
- +11 or trisomy 11 (solely) KMT2A
- +13 or trisomy 13
- +14 or trisomy 14 (solely)
- +15 or trisomy 15 (as sole autosomal abnormality)
- +16 or trisomy 16 (solely)
- +18 or trisomy 18 in lymphoproliferative disorders
- +20 or trisomy 20 (solely)
- +21 or trisomy 21
- +6 or trisomy 6
- +7 or trisomy 7 (solely)
- +8 or trisomy 8
- +9 or trisomy 9
- -21 or monosomy 21 (solely)
- -7/del(7q) in adults
- -7/del(7q) in childhood
- 11q23 rearrangements (KMT2A) in leukaemia
- 12p abnormalities in myeloid malignancies
- 1q translocations (unbalanced) in myeloid malignancies
- 1q triplication in hematologic malignancies
- 3q26 rearrangements (MECOM) in myeloid malignancies
- Atypical Chronic Myeloid Leukemia (aCML)
- Childhood myelodysplastic syndromes
- Classification of myelodysplasic syndromes
- Congenital leukaemias
- Infant leukaemias
- Isolated tetrasomy 8 in AML, MDS and MPD
- MLL amplification in leukemia
- Monosomal karyotype (MK) in myeloid malignancies
- Neonatal leukaemias
- Refractory anemia (RA)
- Refractory anemia with excess blasts (RAEB)
- Refractory anemia with ringed sideroblasts (RARS)
- Trisomy 19
- Trisomy 2
- Y loss in leukemia
- del (3q)
- del (13q)
- del(13q) in myeloid malignancies
- del(16)(q22) CBFB/MYH11
- del(17p) in myeloid malignancies
- del(20q) in myeloid malignancies
- del(21)(q21q22) USP16/RUNX1
- del(5q) in myeloid neoplasms
- del(9q) solely
- dic(17;20)(p11.2;q11.2)
- dic(1;15)(p11;p11)
- i(17q) solely in myeloid malignancies
- i(5)(p10) in acute myeloid leukemia
- ider(20q) in Myeloid Malignancies
- idic(X)(q13)
- ins(3;3)(q26;q21q26) PSMD2/MECOM
- inv(11)(p15q22) NUP98/DDX10
- inv(11)(q21q23) KMT2A/MAML2 in therapy related leukemias
- inv(12)(p13q15) ETV6/PTPRR
- inv(16)(p13q22) CBFB/MYH11
- inv(18)(p11q21)
- inv(3)(q21q26) PSMD2/MECOM
- inv(6)(p15q13)
- inv(6)(p25q13)
- t(10;12)(q24;p13) ETV6/GOT1
- t(10;16)(q22;p13) KAT6B/CREBBP
- t(11;11)(p15;q22) NUP98/DDX10
- t(11;14)(p15;q22) AP2A2/NID2
- t(11;16)(q23;p13.3) KMT2A/CREBBP
- t(11;17)(q23;q25) KMT2A/SEPT9
- t(11;20)(p15;q11) NUP98/TOP1
- t(11;21)(q13;q22) RUNX1/MACROD1
- t(12;12)(p13;q13) ETV6/BAZ2A
- t(12;12)(p13;q13) HMGA2/?
- t(12;13)(p12;q12-14) ETV6/CDX2
- t(12;13)(p13;q14) LIN00598/ETV6
- t(12;14)(q13;q31) HMGA2/?
- t(12;17)(p13;p13) ETV6/PER1
- t(12;18)(p13;q12) ETV6/SETBP1
- t(12;20)(q15;q11.2) HMGA2 truncated
- t(12;22)(p13;q12) MN1/ETV6
- t(14;21)(q22;q22) RUNX1/?
- t(15;21)(q22;q22) RUNX1/?
- t(16;16)(p13;q22) CBFB/MYH11
- t(16;21)(q24;q22) RUNX1/CBFA2T3
- t(1;11)(p32;q23) KMT2A/EPS15
- t(1;12)(p36;p13) ETV6/MDS2
- t(1;12)(q21;p13) ETV6/ARNT
- t(1;12)(q21;q24)
- t(1;16)(q11;q11)
- t(1;18)(q10;q10)
- t(1;19)(p13;p13.1)
- t(1;2)(p36;p21) PRDM16 and LINC00982/?
- t(1;21)(p36;q22) RUNX1/PRDM16
- t(1;3)(p36;p21)
- t(1;3)(p36;q21) PSMD2/PRDM16
- t(1;6)(p36;p21)
- t(1;7)(q10;p10)
- t(20;21)(q13.2;q22.12) ZFP64/RUNX1
- t(20;21)(q13;q22) RUNX1/?
- t(2;11)(p21;q23) KMT2A/?
- t(2;11)(q31;p15) NUP98/HOXD11
- t(2;11)(q31;p15) NUP98/HOXD13
- t(2;12)(q31;p13) ETV6/?
- t(2;3)(p15-23;q26-27) ?/MECOM
- t(2;3)(p15-23;q26-27) ?/MECOM
- t(2;4)(p23;q25-q35)
- t(3;11)(p25;p15) ANKRD28/NUP98
- t(3;11)(q12;p15) NUP98/LNP1
- t(3;12)(q26;p13) ETV6/EVI1
- t(3;12)(q26;p13) ETV6/MECOM
- t(3;16)(q21;q22)
- t(3;18)(q26;q11) ?/MECOM
- t(3;21)(q26;q22) RUNX1/MECOM
- t(3;3)(p24;q26) ?/MECOM
- t(3;3)(q21;q26) PSMD2/MECOM
- t(3;4)(p21;q34)
- t(3;5)(q21;q31)
- t(3;5)(q25;q34) NPM1/MLF1
- t(3;8)(q26;q24) PVT1/MECOM
- t(4;11)(p12;q23) KMT2A/FRYL
- t(4;5)(q31;q31)
- t(5;11)(q31;q23) KMT2A/ARHGAP26
- t(5;12)(q13;p13) ?/ETV6
- t(5;12)(q31;p13) ETV6/ACSL6 in MDS,AML and AEL
- t(5;12)(q33;p13) ETV6/PDGFRB
- t(5;16)(q32;p13) NDE1/PDGFRB
- t(5;17)(q33;p11.2) SPECC1/PDGFRB
- t(5;17)(q33;p13) RABEP1/PDGFRB
- t(5;21)(q13;q22) RUNX1/?
- t(5;7)(q33;q11) HIP1/PDGFRB
- t(6;12)(p21;p13) CCND3/ETV6 in lymphoid malignancies
- t(6;20)(q13;q12) LMBRD1/CHD6
- t(6;21)(p22;q22) RUNX1-?
- t(6;8)(q27;p12) FGFR1OP/FGFR1
- t(6;9)(p22;q34) DEK/NUP214
- t(7;12)(p12;q13) HMGA2 truncated
- t(7;12)(q36;p13) MNX1/ETV6
- t(8;12)(q12;p13)
- t(8;12)(q22;q13) HMGA2/?
- t(8;13)(p11;q12) ZMYM2/FGFR1
- t(8;21)(q23;q22) RUNX1/ZFPM2
- t(8;9)(p22;p24) PCM1/JAK2
- t(9;12)(p24;p13) ETV6/JAK2
- t(9;12)(q22;p12) ETV6/SYK
- t(9;12)(q34;p13) ETV6/ABL1
- t(X;20)(q13;q13.3)
- t(Y;1)(q12;q12)
Treatment Related Leukaemias (t-ANLL)
- +11 or trisomy 11 (solely) KMT2A
- +20 or trisomy 20 (solely)
- +4 or trisomy 4
- +8 or trisomy 8
- -7/del(7q) in adults
- -7/del(7q) in childhood
- 11p15 rearrangements (NUP98) in treatment related leukemia
- 11q23 rearrangements (KMT2A) in leukaemia
- 11q23 rearrangements (KMT2A) in therapy related leukaemias
- 12p abnormalities in myeloid malignancies
- 12p13 rearrangements (ETV6) in treatment related leukemia
- 21q22 rearrangements (RUNX1) in treatment related leukemia
- 3q21q26 rearrangements (RPN1/MECOM) in treatment related leukemia
- Biphenotypic Acute Leukaemia (BAL)
- Childhood myelodysplastic syndromes
- Classification of acute myeloid leukemias
- Classification of myelodysplasic syndromes
- MLL amplification in leukemia
- del(13q) in myeloid malignancies
- del(16)(q22) CBFB/MYH11
- del(17p) in myeloid malignancies
- del(5q) in myeloid neoplasms
- dic(17;20)(p11.2;q11.2)
- inv(11)(q21q23) KMT2A/MAML2 in therapy related leukemias
- inv(16)(p13q22) CBFB/MYH11
- inv(16)(p13q22) CBFB/MYH11 in treatment related leukemia
- inv(6)(p15q13)
- t(10;11)(p12;q23) KMT2A/MLLT10
- t(11;11)(q13;q23) KMT2A/ARHGEF17
- t(11;12)(p15;q13) NUP98/?
- t(11;12)(q23;q13) /HMGA2
- t(11;14)(q23;q32) KMT2A/CEP170B
- t(11;15)(q23;q14) KMT2A/CASC5
- t(11;16)(q23;p13.3) KMT2A/CREBBP
- t(11;17)(q23;p13) KMT2A/GAS7
- t(11;17)(q23;q25) KMT2A/SEPT9
- t(11;19)(q23;p13.1) KMT2A/ELL
- t(11;19)(q23;p13.3) KMT2A/MLLT1
- t(11;20)(p15;q11) NUP98/TOP1
- t(11;22)(q23;q13) KMT2A/EP300
- t(12;13)(p13;q14) LIN00598/ETV6
- t(12;21)(q24;q22) RUNX1/?
- t(14;21)(q22;q22) RUNX1/?
- t(15;17)(q22;q21) in treatment related leukemia
- t(15;17)(q24;q21) PML/RARA
- t(15;21)(q22;q22) RUNX1/?
- t(16;16)(p13;q22) CBFB/MYH11
- t(16;21)(q24;q22) RUNX1/CBFA2T3
- t(17;21)(q11.2;q22) RUNX1/?
- t(18;21)(q21;q22) RUNX1/?
- t(19;21)(q13.4;q22) RUNX1 truncated
- t(1;11)(q23;p15) NUP98/PRRX1
- t(1;12)(q21;q24)
- t(1;21)(p22;q22) RUNX1/CLCA2
- t(1;21)(p36;q22) RUNX1/PRDM16
- t(1;3)(p36;p21)
- t(1;3)(p36;q21) PSMD2/PRDM16
- t(1;6)(p36;p21)
- t(1;7)(p36;q34)
- t(1;7)(q10;p10)
- t(2;11)(q31;p15) NUP98/HOXD11
- t(2;11)(q31;p15) NUP98/HOXD13
- t(2;11)(q37;q23) KMT2A/SEPT2
- t(2;19)(p11;p13)
- t(2;3)(p15-23;q26-27) ?/MECOM
- t(2;3)(p15-23;q26-27) ?/MECOM
- t(2;8)(p23;p11) KAT6A/ASXL2
- t(3;11)(p21;q23) KMT2A/NCKIPSD
- t(3;11)(q25;q23) KMT2A/GMPS
- t(3;11)(q28;q23) KMT2A/LPP
- t(3;12)(q26;q21) ?/MECOM
- t(3;17)(q26;q22) ?/MECOM
- t(3;21)(q26;q22) RUNX1/MECOM
- t(3;21)(q26;q22) RUNX1/MECOM in treatment related leukemia
- t(3;6)(q25;q26) ?/MECOM
- t(4;11)(p12;q23) KMT2A/FRYL
- t(4;11)(q21;q23) KMT2A/AFF1
- t(4;12)(q12;p13) CHIC2/ETV6
- t(5;11)(q31;q23) KMT2A/ARHGAP26
- t(6;11)(q27;q23) KMT2A/MLLT4
- t(6;21)(p22;q22) RUNX1-?
- t(6;9)(p22;q34) DEK/NUP214
- t(8;16)(p11;p13) KAT6A/CREBBP
- t(8;16)(p11;p13) KAT6A/CREBBP in treatment related leukemia
- t(8;21)(q22;q22) RUNX1/RUNX1T1
- t(8;21)(q22;q22) RUNX1/RUNX1T1 in treatment related leukemia
- t(9;11)(p22;q23) KMT2A/MLLT3
- t(9;21)(p22;q22)
- t(9;22)(q34;q11) BCR/ABL1 in treatment related leukemia
Acute Non Lymphocytic Leukaemias (ANLL)
- +10 or trisomy 10 (solely)
- +11 or trisomy 11 (solely) KMT2A
- +13 or trisomy 13
- +13,+13 or tetrasomy 13
- +14 or trisomy 14 (solely)
- +15 or trisomy 15 (as sole autosomal abnormality)
- +16 or trisomy 16 (solely)
- +18 or trisomy 18 in lymphoproliferative disorders
- +21 or trisomy 21
- +22 or trisomy 22 (solely?)
- +4 or trisomy 4
- +6 or trisomy 6
- +7 or trisomy 7 (solely)
- +8 or trisomy 8
- +9 or trisomy 9
- -21 or monosomy 21 (solely)
- -7/del(7q) in adults
- -7/del(7q) in childhood
- 11q23 rearrangements (KMT2A) in de novo childhood acute myeloid leukemia
- 11q23 rearrangements (KMT2A) in leukaemia
- 12p abnormalities in myeloid malignancies
- 15q13-15 Rearrangements
- 1q translocations (unbalanced) in myeloid malignancies
- 1q triplication in hematologic malignancies
- 3q26 rearrangements (MECOM) in myeloid malignancies
- Acute Erythroid leukaemias
- Acute basophilic leukemia
- Acute megakaryoblastic leukemia (AMegL)
- Acute promyelocytic leukemia (APL)
- Biphenotypic Acute Leukaemia (BAL)
- Classification of acute myeloid leukemias
- Congenital leukaemias
- Infant leukaemias
- Isolated tetrasomy 8 in AML, MDS and MPD
- M0 acute non lymphocytic leukemia (M0-ANLL)
- M3/M3v acute myeloid leukemia (AML M3/M3v)
- M3/M3v acute non lymphocytic leukemia (M3-ANLL)
- M7 acute non lymphocytic leukemia (M7-ANLL)
- MLL amplification in leukemia
- Monosomal karyotype (MK) in myeloid malignancies
- Neonatal leukaemias
- Systemic mast cell disease (SMCD)
- Trisomy 19
- Trisomy 2
- Trisomy 5
- Y loss in leukemia
- del (13q)
- del(11)(q23q23) KMT2A/ARHGEF12
- del(11)(q23q23) KMT2A/CBL
- del(16)(q22) CBFB/MYH11
- del(17)(q21q24) PRKAR1A/RARA
- del(17p) in myeloid malignancies
- del(20q) in myeloid malignancies
- del(21)(q21q22) USP16/RUNX1
- del(4)(q12q12) FIP1L1/PDGFRA
- del(5q) in myeloid neoplasms
- del(9q) solely
- dic(17;20)(p11.2;q11.2)
- dic(1;15)(p11;p11)
- dup(17)(q12q21) STAT5B/RARA
- i(5)(p10) in acute myeloid leukemia
- i(8)(q10) in acute myeloid leukaemia
- ider(20q) in Myeloid Malignancies
- idic(7)(q11.2)
- idic(X)(q13)
- ins(3;3)(q26;q21q26) PSMD2/MECOM
- ins(X;11)(q26;q23q23)
- inv(11)(p15q22) NUP98/DDX10
- inv(12)(p13q15) ETV6/PTPRR
- inv(14)(q11q32.1) TRA-TRD/TCL1A
- inv(16)(p13q22) CBFB/MYH11
- inv(16)(p13q24) CBFA2T3/GLIS2
- inv(2)(p23q13) RANBP2/ALK
- inv(3)(q21q26) PSMD2/MECOM
- inv(3)(q21q26) PSMD2/MECOM
- inv(6)(p25q13)
- inv(8)(p11q13) KAT6A/NCOA2
- t(10;11)(p11.2;q23) KMT2A/ABI1
- t(10;11)(p12;q23) KMT2A/MLLT10
- t(10;11)(p12;q23) KMT2A/NEBL
- t(10;11)(p13;q21) PICALM/MLLT10
- t(10;11)(q22;q23) KMT2A/TET1
- t(10;16)(q22;p13) KAT6B/CREBBP
- t(10;17)(p15;q21) ZMYND11/MBTD1
- t(11;11)(p15;q22) NUP98/DDX10
- t(11;11)(q23;q23) KMT2A/CBL
- t(11;12)(p15;p13) NUP98/KDM5A
- t(11;12)(q23;q13) KMT2A/SARNP
- t(11;16)(q23;p13.3) KMT2A/CREBBP
- t(11;17)(p15;p13) NUP98/PHF23
- t(11;17)(q13;q21) NUMA1/RARA
- t(11;17)(q23;p13) KMT2A/GAS7
- t(11;17)(q23;q12) KMT2A/RARA
- t(11;17)(q23;q12-21) KMT2A/LASP1
- t(11;17)(q23;q12-21) KMT2A/MMLT6
- t(11;17)(q23;q21) ZBTB16/RARA
- t(11;17)(q23;q25) KMT2A/SEPT9
- t(11;19)(q23;p13) KMT2A/SH3GL1
- t(11;19)(q23;p13.1) KMT2A/ELL
- t(11;19)(q23;p13.3) KMT2A/MLLT1
- t(11;20)(p15;q11) NUP98/TOP1
- t(11;21)(p14;q22) RUNX1/KIAA1549L
- t(11;21)(q13;q22) RUNX1/MACROD1
- t(11;21)(q21;q22) RUNX1/LPXN
- t(11;22)(q23;q11.2) KMT2A/SEPT5
- t(12;12)(p13;q13) ETV6/BAZ2A
- t(12;13)(p12;q12-14) ETV6/CDX2
- t(12;13)(p13;q14) LIN00598/ETV6
- t(12;15)(p13;q25) ETV6/NTRK3
- t(12;17)(p11;q11) in AML
- t(12;17)(p13;p13) ETV6/PER1
- t(12;17)(p13;q11) TAF15/ZNF384
- t(12;18)(p13;q12) ETV6/SETBP1
- t(12;19)(q13;q13)
- t(12;21)(q12;q22) RUNX1 truncated
- t(12;22)(p13;q12) EWSR1/ZNF384
- t(12;22)(p13;q12) MN1/ETV6
- t(14;14)(q11;q32.1) TRA-TRD/TCL1A
- t(14;22)(q32;q11) IGH/IGL
- t(15;17)(q24;q21) PML/RARA
- t(16;16)(p13;q22) CBFB/MYH11
- t(16;21)(p11;q22) FUS/ERG
- t(16;21)(q24;q22) RUNX1/CBFA2T3
- t(17;17)(q21;q21) STAT5B/RARA
- t(17;17)(q21;q24) PRKAR1A/RARA
- t(17;21)(q11.2;q22) RUNX1/?
- t(1;11)(p32;q23) KMT2A/EPS15
- t(1;11)(q21;q23) KMT2A/MLLT11
- t(1;12)(q21;q24)
- t(1;12)(q25;p13) ETV6/ABL2
- t(1;14)(q25;q32) IGH/LHX4
- t(1;16)(q12;q24)
- t(1;18)(q25;q23)
- t(1;19)(p13;p13.1)
- t(1;19)(q23;p13) TCF3/PBX1
- t(1;2)(q12;q37)
- t(1;21)(p32;q22) RUNX1/?
- t(1;21)(p35;q22) RUNX1/YTHDF2
- t(1;21)(p36;q22) RUNX1/PRDM16
- t(1;21)(q12;q22) RUNX1/?
- t(1;21)(q21;q22) RUNX1/ZNF687
- t(1;22)(p13;q13) RBM15/MKL1
- t(1;3)(p36;p21)
- t(1;3)(p36;q21) PSMD2/PRDM16
- t(1;7)(p36;q34)
- t(1;7)(q10;p10)
- t(1;8)(p22-p32;q22-q23)
- t(20;21)(q11;q22) RUNX1/?
- t(20;21)(q13;q22) RUNX1/?
- t(2;11)(p21;q23) KMT2A/?
- t(2;11)(q31;p15) NUP98/HOXD11
- t(2;11)(q31;p15) NUP98/HOXD13
- t(2;11)(q37;q23) KMT2A/SEPT2
- t(2;14)(p13-16;q32) IGH/BCL11A
- t(2;19)(p11;p13)
- t(2;2)(p23;q13) RANBP2/ALK
- t(2;21)(p11;q22) RUNX1/?
- t(2;3)(p15-23;q26-27) ?/MECOM
- t(2;3)(p16;q26) BCL11A/MECOM
- t(2;3)(p21;q26) THADA/MECOM
- t(2;4)(p23;q25-q35)
- t(3;11)(p25;p15) ANKRD28/NUP98
- t(3;11)(q12;p15) NUP98/LNP1
- t(3;11)(q13.13;q23) KMT2A/KIAA1524
- t(3;12)(q26;p13) ETV6/EVI1
- t(3;12)(q26;p13) ETV6/MECOM
- t(3;16)(q21;q22)
- t(3;17)(q26;q22) ?/MECOM
- t(3;21)(p12;q22) RUNX1/?
- t(3;21)(q26;q22) RUNX1/MECOM
- t(3;3)(q21;q26) PSMD2/MECOM
- t(3;4)(p21;q34)
- t(3;5)(p21;q32) RBM6/CSF1R
- t(3;5)(q21;q31)
- t(3;5)(q25;q34) NPM1/MLF1
- t(3;5)(q26;q34) ?/MECOM
- t(3;6)(q25;q26) ?/MECOM
- t(3;7)(q26;q21) MECOM/CDK6
- t(3;8)(q21;q24) in myeloid malignancies
- t(3;8)(q26;q24) PVT1/MECOM
- t(4;11)(q21;q23) KMT2A/AFF1
- t(4;11)(q35;q23) KMT2A/SORBS2
- t(4;12)(q12;p13) CHIC2/ETV6
- t(4;17)(q12;q21) FIP1L1/RARA
- t(4;21)(q31;q22) RUNX1/SH3D19
- t(4;5)(q31;q31)
- t(5;11)(q31;q23) KMT2A/ARHGAP26
- t(5;11)(q35;p15.5) NUP98/NSD1
- t(5;11)(q35;q12) NSD1/FEN1
- t(5;12)(p13;p13) NIPBL/ETV6
- t(5;12)(q13;p13) ?/ETV6
- t(5;12)(q31;p13) ETV6/ACSL6 in MDS,AML and AEL
- t(5;12)(q33;p13) ERC1/PDGFRB
- t(5;14)(q33;q32) PDGFRB/TRIP11
- t(5;14)(q35;q11) TRD/NKX2-5
- t(5;16)(q33;q22)
- t(5;17)(q35;q21) NPM1/RARA
- t(5;21)(q13;q22) RUNX1/?
- t(6;11)(q13;q23) KMT2A-SMAP1
- t(6;11)(q15;q23) KMT2A/?
- t(6;11)(q27;q23) KMT2A/MLLT4
- t(6;14)(q25-27;q32) BCL11B/?
- t(6;20)(q13;q12) LMBRD1/CHD6
- t(6;22)(p21;q11)
- t(6;8)(q27;p12) FGFR1OP/FGFR1
- t(6;9)(p22;q34) DEK/NUP214
- t(7;11)(p15;p15) NUP98/HOXA9
- t(7;12)(q36;p13) MNX1/ETV6
- t(7;14)(q21;q13)
- t(7;14)(q22;q11)
- t(7;14)(q35;q32.1) TRB/TCL1A
- t(7;21)(p15;q22) RUNX1/?
- t(7;21)(p22;q22) RUNX1/USP42
- t(7;8)(q34;p11) TRIM24/FGFR1
- t(8;11)(p11;p15) NUP98/WHSC1L1
- t(8;11)(p12;p15) ?/FGFR1
- t(8;12)(q12;p13)
- t(8;12)(q13;p13) ETV6/NCOA2
- t(8;16)(p11;p13) KAT6A/CREBBP
- t(8;19)(p11;q13) ERVK-6/FGFR1
- t(8;19)(p11;q13) KAT6A/?
- t(8;20)(p11;q13) KAT6A/NCOA3
- t(8;21)(q22;q22) RUNX1/RUNX1T1
- t(8;21)(q24;q22) RUNX1/TRPS1
- t(8;22)(p11;q13) KAT6A/EP300
- t(8;9)(p22;p24) PCM1/JAK2
- t(9;11)(p22;p15) NUP98/PSIP1
- t(9;11)(p22;q23) KMT2A/MLLT3
- t(9;11)(q34;p15) NUP98/PRRX2
- t(9;11)(q34;q23) FNBP1/KMT2A
- t(9;11)(q34;q23) KMT2A/DAB2IP
- t(9;12)(q34;p13) ETV6/ABL1
- t(9;21)(q34;q22) RUNX1 truncated
- t(9;22)(q34;q11) BCR/ABL1 in AML
- t(9;9)(q34;q34) SET/NUP214
- t(X;10)(p10;p10)
- t(X;11)(q13;q23) KMT2A/FOXO4
- t(X;11)(q22;q23) KMT2A/?
- t(X;11)(q24;q23) KMT2A/SEPT6
- t(X;11)(q26;q23)
- t(X;17)(p11;q21) BCOR/RARA
- t(X;21)(p22;q22) RUNX1/RPL22
- t(X;21)(q26;q22) ELF4/ERG
- t(X;6)(p11;q23) MYB/GATA1
B-Cell Acute Lymphocytic Leukaemias (B-ALL)
- +10 or trisomy 10 (solely)
- +13 or trisomy 13
- +15 or trisomy 15 (as sole autosomal abnormality)
- +16 or trisomy 16 (solely)
- +18 or trisomy 18 in lymphoproliferative disorders
- +21 or trisomy 21
- +4 or trisomy 4
- +6 or trisomy 6
- +8 or trisomy 8
- +9 or trisomy 9
- -21 or monosomy 21 (solely)
- 11q23 rearrangements (KMT2A) in childhood acute lymphoblastic leukemia
- 11q23 rearrangements (KMT2A) in leukaemia
- 12p rearrangements (ETV6) in ALL
- 15q13-15 Rearrangements
- 9p Rearrangements in ALL
- Biphenotypic Acute Leukaemia (BAL)
- Congenital leukaemias
- High hyperdiploid acute lymphoblastic leukaemia
- Infant leukaemias
- Near haploid acute lymphoblastic leukaemia
- Neonatal leukaemias
- Severe hypodiploid acute lymphoblastic leukaemia
- Trisomy 5
- del(13q) in ALL
- del(6q) abnormalities in lymphoid malignancies
- del(9)(p13p24) PAX5/JAK2
- dic(3;9)(p14;p13) PAX5/FOXP1
- dic(7;9)(p11-12;p12-13) PAX5/LOC392027
- dic(7;9)(p11-13;p11)
- dic(9;12)(p13;p12) PAX5/SLCO1B3
- dic(9;12)(p13;p13) PAX5/ETV6
- dic(9;16)(p13;q11) PAX5/?
- dic(9;17)(p13;q11) PAX5/TAOK1
- dic(9;18)(p13;q11) PAX5/ZNF521
- dic(9;20)(p11-13;q11) PAX5/Various
- dup(21q) amplified (RUNX1)
- i(6)(p10)
- i(9q) in ALL
- ins(5;11)(q31;q13q23) KMT2A/AFF4
- ins(X;11)(q26;q23q23)
- inv(11)(q13q23) KMT2A/BTBD18
- inv(14)(q11q32) CEBPE/IGH
- inv(14)(q11q32.1) TRA-TRD/TCL1A
- inv(19)(p13q13) TCF3/TFPT
- inv(9)(p13p24) PAX5/JAK2
- t(10;11)(p12;q23) KMT2A/MLLT10
- t(10;11)(p13;q21) PICALM/MLLT10
- t(10;11)(q22;q23) KMT2A/TET1
- t(11;16)(q23;p13.3) KMT2A/CREBBP
- t(11;17)(q23;p13) KMT2A/GAS7
- t(11;17)(q23;q25) KMT2A/SEPT9
- t(11;19)(q23;p13.3) KMT2A/ACER1
- t(11;19)(q23;p13.3) KMT2A/MLLT1
- t(11;20)(q23;q11) KMT2A/MAPRE1
- t(12;12)(p13;q13) ETV6/BAZ2A
- t(12;13)(p12;q12-14) ETV6/CDX2
- t(12;13)(p13;q14) LIN00598/ETV6
- t(12;14)(p13;q32) IGH/ETV6
- t(12;17)(p13;q11) TAF15/ZNF384
- t(12;17)(p13;q11-21) in ALL
- t(12;19)(p13;p13) TCF3/ZNF384
- t(12;21)(p13;q22) ETV6/RUNX1
- t(12;22)(p13;q12) EWSR1/ZNF384
- t(13;19)(q14;p13) TCF3/?
- t(14;14)(q11;q32) CEBPE/IGH
- t(14;14)(q11;q32.1) TRA-TRD/TCL1A
- t(14;18)(q32;q21) IGH/BCL2
- t(14;19)(q32;q13) IGH/CEBPA
- t(14;20)(q32;q13) IGH/CEBPB
- t(17;19)(q22;p13) TCF3/HLF
- t(18;22)(q21;q11) IGL/BCL2
- t(19;19)(p13;q13) TCF3/TFPT
- t(1;11)(p32;q23) KMT2A/EPS15
- t(1;14)(q21;q32)
- t(1;14)(q21;q32) BCL9/IGH
- t(1;14)(q25;q32) IGH/LHX4
- t(1;18)(q25;q23)
- t(1;19)(q23;p13) TCF3/PBX1
- t(1;2)(q12;q37)
- t(1;22)(q21;q11)
- t(1;22)(q21;q11) IGL/BCL9
- t(1;3)(p36;p21)
- t(1;5)(q22;q33) PDE4DIP/PDGFRB
- t(1;9)(p13;p12) PAX5/HIPK1
- t(1;9)(p34;q34) SFPQ/ABL1
- t(1;9)(q24;q34) RCSD1/ABL1
- t(2;11)(p21;q23) KMT2A/?
- t(2;14)(p13-16;q32) IGH/BCL11A
- t(2;18)(p11;q21) IGK/BCL2
- t(2;8)(p12;q24) IGK/MYC
- t(2;9)(p11;p13) PAX5/?
- t(2;9)(q37;q34) INPP5D-ABL1
- t(3;11)(q21;q23) KMT2A/EEFSEC
- t(4;11)(p12;q23) KMT2A/FRYL
- t(4;11)(q21;q23) KMT2A/AFF1
- t(4;12)(q12;p13) CHIC2/ETV6
- t(5;11)(q31;q23) KMT2A/ARHGAP26
- t(5;14)(q31;q32) IGH/IL3
- t(5;15)(p15;q11-13)
- t(5;9)(q14.1;p24) SSBP2/JAK2
- t(6;12)(p21;p13) CCND3/ETV6 in lymphoid malignancies
- t(6;14)(p22;q32) IGH/ID4
- t(6;14)(q25-27;q32) BCL11B/?
- t(6;22)(p21;q11)
- t(7;12)(q36;p13) MNX1/ETV6
- t(7;14)(q35;q32.1) TRB/TCL1A
- t(7;9)(q11.2;p13.2) PAX5/AUTS2
- t(7;9)(q11;p12) PAX5/POM121
- t(7;9)(q11;p13) PAX5/ELN
- t(8;12)(q13;p13) ETV6/NCOA2
- t(8;14)(q11;q32) IGH/CEBPD
- t(8;14)(q24;q11) TRA/MYC
- t(8;14)(q24;q32) IGH/MYC
- t(8;22)(q24;q11) IGL/MYC
- t(8;9)(p22;p24) PCM1/JAK2
- t(8;9)(q24;p13) ?/MYC
- t(8;9)(q24;q13)
- t(9;10)(q34;q22) ZMIZ1/ABL1
- t(9;12)(p24;p13) ETV6/JAK2
- t(9;12)(q34;p13) ETV6/ABL1
- t(9;13)(p12;q21) PAX5/DACH1
- t(9;15)(p13;q24) PAX5/GOLGA6A
- t(9;15)(p13;q24) PAX5/PML
- t(9;17)(p13;p12) PAX5/NCOR1
- t(9;22)(p13;q13) PAX5/BRD1
- t(9;22)(q34;q11) BCR/ABL1 in ALL
- t(9;9)(p13;p24) PAX5/JAK2
- t(X;11)(q22;q23) KMT2A/?
- t(X;11)(q26;q23)
- t(X;9)(q21;p13) PAX5/DACH2
T-Cell Acute Lymphocytic Leukaemias (T-ALL)
- +20 or trisomy 20 (solely)
- +4 or trisomy 4
- +7 or trisomy 7 (solely)
- +8 or trisomy 8
- +9 or trisomy 9
- 11q23 rearrangements (KMT2A) in childhood acute lymphoblastic leukemia
- 11q23 rearrangements (KMT2A) in leukaemia
- 12p rearrangements (ETV6) in ALL
- 15q13-15 Rearrangements
- 1p32 rearrangements
- 9p Rearrangements in ALL
- Biphenotypic Acute Leukaemia (BAL)
- NK cell neoplasias
- NUP214/ABL1 fusion gene on amplified episomes
- T-lineage acute lymphoblastic leukemia (T-ALL)
- del(11)(p12p13) LMO2
- del(13q) in ALL
- del(6q) abnormalities in lymphoid malignancies
- del(9q) solely
- dic(9;12)(p13;p13) PAX5/ETV6
- i(6)(p10)
- inv(14)(q11q32.1) TRA-TRD/TCL1A
- inv(7)(p15q34) TRB/HOXA10
- t(10;11)(p13;q21) PICALM/MLLT10
- t(10;11)(q25;p15) NUP98/ADD3
- t(10;14)(q24;q11) TRD/TLX1
- t(11;14)(p13;q11) TRD/LMO2
- t(11;14)(p15;q11) TRD/LMO1
- t(11;18)(p15;q12) NUP98/SETBP1
- t(11;19)(q23;p13.3) KMT2A/MLLT1
- t(12;12)(p13;q13) ETV6/BAZ2A
- t(12;13)(p12;q12-14) ETV6/CDX2
- t(12;14)(p13;q11) TRA or TRD/CCND2
- t(14;14)(q11;q32.1) TRA-TRD/TCL1A
- t(14;21)(q11;q22) TRA/OLIG2
- t(1;12)(q21;p13) ETV6/ARNT
- t(1;14)(p32;q11) TRA/TAL1
- t(1;19)(q23;p13) TCF3/PBX1
- t(1;2)(p36;p21) PRDM16 and LINC00982/?
- t(1;3)(p32;p21) TCTA/TAL1
- t(1;5)(p32;q31) ?/TAL1
- t(1;7)(p32;q34) TRB/TAL1
- t(1;7)(p34;q34) TRB/LCK
- t(2;14)(p13-16;q32) IGH/BCL11A
- t(2;21)(q11;q22)
- t(3;11)(q12;p15) NUP98/LNP1
- t(3;11)(q29;p15) NUP98/IQCG
- t(4;11)(q21;p15) NUP98/RAP1GDS1
- t(4;11)(q21;q23) KMT2A/AFF1
- t(4;21)(q31;q22) RUNX1/?
- t(5;12)(q13;p13) ?/ETV6
- t(5;14)(q35;q11) TRD/NKX2-5
- t(5;14)(q35;q32) BCL11B/TLX3
- t(5;14)(q35;q32.2) BCL11B/TLX3 and NKX2-5
- t(5;17)(q13;q21)
- t(5;6)(q33-34;q23) CEP85L/PDGFRB
- t(5;7)(q35;q21) TLX3/CDK6
- t(6;11)(q27;q23) KMT2A/MLLT4
- t(6;7)(q23;q34) TRB/MYB and AHI1
- t(7;10)(q34;q24) TRD/TLX1
- t(7;11)(q35;p13) TBB/LMO2
- t(7;12)(q34;p13) TRB/CCND2
- t(7;14)(p15;q11) TRD/HOXA10
- t(7;14)(q35;q32.1) TRB/TCL1A
- t(7;19)(q34;p13) TRB/LYL1
- t(7;7)(p15;q34) TRB/HOXA10
- t(7;9)(q34;q32) TRB/TAL2
- t(7;9)(q34;q34) TRB-NOTCH1
- t(8;12)(q13;p13) ETV6/NCOA2
- t(8;14)(q24;q11) TRA/MYC
- t(8;21)(q24;q22) RUNX1/TRPS1
- t(8;9)(p22;p24) PCM1/JAK2
- t(9;12)(p24;p13) ETV6/JAK2
- t(9;12)(q34;p13) ETV6/ABL1
- t(9;14)(q34;q32) EML1/ABL1
- t(9;22)(q34;q11) BCR/ABL1 in ALL
- t(X;11)(q13;q23) KMT2A/FOXO4
- t(X;7)(q22;q34) IRS4/TRB
Non Hodgkin Lymphomas (NHL)
- Classification of B-cell non-Hodgkin's lymphomas (NHL)
- +12 or trisomy 12
- +18 or trisomy 18 in lymphoproliferative disorders
- +20 or trisomy 20 (solely)
- +3 or trisomy 3 in non Hodgkin's lymphoma (NHL)
- +8 or trisomy 8
- 12p rearrangements in CLL
- 15q13-15 Rearrangements
- 1q triplication in hematologic malignancies
- 3q27 rearrangements (BCL6) in non Hodgkin lymphoma
- ALK -positive diffuse large B-cell lymphoma
- Anaplastic B-cell lymphoma
- Anaplastic large cell lymphoma (ALCL)
- Angioimmunoblastic T-cell lymphoma
- Burkitt's lymphoma (BL)
- Centroblastic lymphoma
- Classification of B-cell non-Hodgkin lymphomas (NHL)
- Classification of T-Cell disorders
- Cutaneous T-cell lymphomas
- Diffuse large cell lymphoma
- Follicular lymphoma (FL)
- Hepatosplenic T-cell lymphoma (HSTCL)
- Hodgkin lymphoma
- Immunoblastic lymphoma
- Intestinal T-cell lymphoma
- Lymphoepithelioid lymphoma
- Lymphoplasmacytic lymphoma
- Mantle cell lymphoma (incomplete)
- Marginal Zone B-cell lymphoma
- Mucosa-associated lymphoid tissue (MALT) lymphoma
- Mycosis fungoides/Sezary's syndrome
- NK cell neoplasias
- Nasal T cell lymphoma
- Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
- Primary cutaneous CD30+ anaplastic large cell lymphoma
- Small lymphocytic lymphoma
- T-cell large granular lymphocyte leukaemia
- T-cell/histiocyte-rich large B cell lymphoma
- Waldenstrom's macroglobulinemia (WM)
- del (13q)
- del(11q) in non-Hodgkin's lymphoma (NHL)
- del(13q) in non-Hodgkin's lymphoma
- del(17p) in non-Hodgkin's lymphoma (NHL)
- del(3)(q27q27) ST6GAL1/BCL6
- del(6q) abnormalities in lymphoid malignancies
- del(7q) in non-Hodgkin's lymphoma (NHL)
- dic(9;12)(p13;p13) PAX5/ETV6
- ins(12;8)(p11;p12p22) FGFR1OP2/FGFR1
- inv(14)(q11q32.1) TRA-TRD/TCL1A
- inv(18)(p11q21)
- inv(2)(p23q35) ATIC/ALK
- inv(7)(p15q34) TRB/HOXA10
- t(10;11)(q22;q23) KMT2A/TET1
- t(10;14)(q24;q11) TRD/TLX1
- t(11;14)(q13;q32) IGH/CCND1
- t(11;18)(q21;q21) BIRC3/MALT1
- t(12;14)(p13;q32) IGH/CCND2
- t(12;22)(p13;q11) IGL/CCND2
- t(14;14)(q11;q32.1) TRA-TRD/TCL1A
- t(14;15)(q32;q11) IGH/NBEAP1
- t(14;18)(q32;q21) IGH/BCL2
- t(14;18)(q32;q21) IGH/MALT1
- t(14;19)(q32;q13) IGH/BCL3
- t(14;22)(q32;q11) IGH/IGL
- t(18;22)(q21;q11) IGL/BCL2
- t(19;22)(q13;q11) BCL3/IGL
- t(1;1)(p36;q21) in Non Hodgkin Lymphoma
- t(1;13)(q32;q14)
- t(1;14)(p22;q32) IGH/BCL10
- t(1;14)(q21;q32)
- t(1;14)(q21;q32) BCL9/IGH
- t(1;14)(q21;q32) FCGR2B/IGH
- t(1;14)(q21;q32) FCRL4/IGH
- t(1;14)(q21;q32) MUC1/IGH
- t(1;16)(q11;q11)
- t(1;19)(q23;p13) TCF3/PBX1
- t(1;2)(p22;p12) IGK/BCL10
- t(1;2)(q25;p23) TPM3/ALK
- t(1;22)(q21;q11)
- t(1;22)(q21;q11) IGL/BCL9
- t(1;3)(p36;p21)
- t(1;3)(q25;q27) GAS5/BCL6
- t(1;7)(q21;q22)
- t(1;8)(p22-p32;q22-q23)
- t(2;12)(p12;p13) IGK/CCND2
- t(2;12)(q31;p13) ETV6/?
- t(2;14)(p13-16;q32) IGH/BCL11A
- t(2;17)(p23;q23) CLTC/ALK
- t(2;17)(p23;q25) RNF213/ALK
- t(2;18)(p11;q21) IGK/BCL2
- t(2;18)(q11;q21) AFF3/BCL2
- t(2;19)(p12;q13) IGK/BCL3
- t(2;19)(p23;p13) TPM4/ALK
- t(2;22)(p23;q11) CLTCL1/ALK
- t(2;22)(p23;q11) MYH9/ALK
- t(2;3)(p12;q27) IGK/BCL6
- t(2;3)(p23;q21) TFG/ALK
- t(2;5)(p23;q35) NPM1/ALK
- t(2;5)(p23;q35) SQSTM1/ALK
- t(2;6)(p12;p25) IRF4/IGK
- t(2;8)(p12;q24) IGK/MYC
- t(2;8)(p15;q24) BCL11A/MYC
- t(2;9)(p23;q33) TRAF1/ALK
- t(3;11)(q27;q23) POU2AF1/BCL6
- t(3;12)(q27;p12) LRMP/BCL6
- t(3;12)(q27;p13) GAPDH/BCL6
- t(3;13)(q27;q14) LCP1/BCL6
- t(3;14)(p14;q32) IGH/FOXP1
- t(3;14)(q21;q32)
- t(3;14)(q27;q32) HSP90AA1/BCL6
- t(3;14)(q27;q32) IGH/BCL6
- t(3;16)(q27;p11) IL21R/BCL6
- t(3;16)(q27;p13) CIITA/BCL6
- t(3;19)(q27;q13) NAPA/BCL6
- t(3;22)(q27;q11) IGL/BCL6
- t(3;3)(q25;q27) MBNL1/BCL6
- t(3;3)(q27;q27) ST6GAL1/BCL6
- t(3;3)(q27;q28) EIF4A2/BCL6
- t(3;3)(q27;q29) TFRC/BCL6
- t(3;4)(q27;p13) RHOH/BCL6
- t(3;6)(q27;p21)
- t(3;6)(q27;p21) PIM1/BCL6
- t(3;6)(q27;p21) SRSF3/BCL6
- t(3;6)(q27;p22) HIST1H4I/BCL6
- t(3;6)(q27;q14) SNHG5/BCL6
- t(3;6)(q27;q15) ?/BCL6
- t(3;7)(q27;p12) IKZF1-BCL6
- t(3;7)(q27;q32) FRA7H/BCL6
- t(3;7)(q27;q32) MIR29A/BCL6
- t(3;8)(q27;q24) BCL6/MYC
- t(3;9)(q26;p23) ?/MECOM
- t(3;9)(q27;p13) GRHPR/BCL6
- t(3;9)(q27;p24) DMRT1/BCL6
- t(3;Var)(q27;Var) in non Hodgkin lymphoma
- t(4;12)(p16;p13) ETV6/FGFR3
- t(4;16)(q26;p13) IL2/TNFRSF17
- t(5;9)(q33;q22) ITK/SYK
- t(6;12)(p21;p13) CCND3/ETV6 in lymphoid malignancies
- t(6;14)(p25.3;q11.2) TRA/IRF4
- t(6;14)(p25;q32) IRF4/IGH
- t(6;20)(q15;q11.2) BACH2/BCL2L1
- t(6;22)(p25;q11) IRF4/IGL
- t(6;7)(p25.3;q32.3) DUSP22/FRA7H
- t(6;8)(q11;q11)
- t(6;8)(q27;p12) FGFR1OP/FGFR1
- t(7;10)(q34;q24) TRD/TLX1
- t(7;14)(q35;q32.1) TRB/TCL1A
- t(7;7)(p15;q34) TRB/HOXA10
- t(7;8)(p12;q24) /MYC
- t(8;12)(p12;p11) FGFR1OP2/FGFR1
- t(8;12)(q24;p12) LRMP/MYC
- t(8;13)(p11;q12) ZMYM2/FGFR1
- t(8;14)(q24;q11) TRA/MYC
- t(8;14)(q24;q32) IGH/MYC
- t(8;22)(q24;q11) IGL/MYC
- t(8;9)(p22;p24) PCM1/JAK2
- t(8;9)(q24;p13) ?/MYC
- t(8;9)(q24;q13)
- t(9;14)(p13;q32) PAX5/IGH
- t(X;14)(p11.4;q32.33) IGH/GPR34
- t(X;2)(q11;p23) MSN/ALK
Chronic Lymphoproliferative Diseases (CLD)
- Classification of B-cell chronic lymphoproliferative disorders (CLD)
- +12 or trisomy 12
- +15 or trisomy 15 (as sole autosomal abnormality)
- +16 or trisomy 16 (solely)
- +18 or trisomy 18 in lymphoproliferative disorders
- +20 or trisomy 20 (solely)
- +8 or trisomy 8
- -21 or monosomy 21 (solely)
- 12p rearrangements in CLL
- 1q rearrangements in multiple myeloma
- 1q triplication in hematologic malignancies
- Adult T-cell leukemia/lymphoma (ATLL)
- B-cell prolymphocytic leukemia (B-PLL)
- Chronic lymphocytic leukaemia (CLL)
- Classification of B-cell chronic lymphoproliferative disorders (CLD)
- Classification of T-Cell disorders
- Fibrogenesis imperfecta ossium
- Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia Variant (HCL-V)
- Lymphomatoid papulosis (LyP) with 6p25.3 rearrangement DUSP22 and IRF4/
- Multiple myeloma
- Plasma cell leukemia (PCL)
- Polyclonal B Lymphocytosis with Binucleated Lymphocytes (PPBL)
- Splenic lymphoma with villous lymphocytes (SLVL)
- T-cell prolymphocytic leukemia (T-PLL)
- del (13q)
- del(13q) in chronic lymphoproliferative diseases
- del(13q) in multiple myeloma
- del(6q) abnormalities in lymphoid malignancies
- del(6q) in Multiple Myeloma
- inv(14)(q11q32.1) TRA-TRD/TCL1A
- inv(19)(p13q13) TCF3/TFPT
- t(11;14)(p11;q32)
- t(11;14)(q13;q32) IGH/CCND1
- t(11;14)(q13;q32) IGH/CCND1 in multiple myeloma
- t(13;19)(q14;p13) TCF3/?
- t(14;14)(q11;q32.1) TRA-TRD/TCL1A
- t(14;18)(q32;q21) IGH/BCL2
- t(14;19)(q32;q13) IGH/BCL3
- t(14;22)(q32;q11) IGH/IGL
- t(18;22)(q21;q11) IGL/BCL2
- t(19;19)(p13;q13) TCF3/TFPT
- t(19;22)(q13;q11) BCL3/IGL
- t(1;14)(q21;q32) FCRL4/IGH
- t(1;3)(p36;q21) PSMD2/PRDM16
- t(1;6)(p35;p25) ?/IRF4
- t(1;6)(p36;p21)
- t(2;14)(p13-16;q32) IGH/BCL11A
- t(2;18)(p11;q21) IGK/BCL2
- t(2;19)(p12;q13) IGK/BCL3
- t(2;6)(p12;p25) IRF4/IGK
- t(2;7)(p11;q21) IGK/CDK6
- t(4;14)(p16;q32) IGH/FGFR3 and WHSC1
- t(6;12)(p21;p13) CCND3/ETV6 in lymphoid malignancies
- t(6;14)(p21;q32) IGH/CCND3
- t(6;14)(p25;q32) IRF4/IGH
- t(6;14)(q25-27;q32) BCL11B/?
- t(6;22)(p21;q11)
- t(6;22)(p25;q11) IRF4/IGL
- t(7;14)(q21;q32) ERVW-1/IgH
- t(7;14)(q21;q32) IGH/CDK6
- t(7;14)(q35;q32.1) TRB/TCL1A
- t(7;22)(q21;q11) IGL/CDK6
- t(8;12)(q24;q22) BTG1/MYC
- t(8;17)(q24;q22) ???BCL3/MYC
- t(9;14)(p13;q32) PAX5/IGH
- t(X;11)(q21;q23) BRWD3/ARHGAP20